Jul 2026
Abstract A020: Engineering developability of anti-CD3 scFv-based multispecific T-cell engagers
Stabilized anti-CD3 scFv not only improve properties of two clinical CD20 Fab-based multispecifics but rescue assembly of a third clinical CD20 molecule, which did not produce with the parental, unmodified scFv or with the industry standard engineered disulfide bond VH44-VK100.
Rob Pejchal, Kevin Schutz, Michael B. Battles et al.
· Clinical Cancer Research · 0 citations